{"classes":[{"categories":[{"measurements":[{"comment":"The median and associated confidence intervals were not reached due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group with events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group with events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group with events.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group with events.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group with events.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"description":"OS was defined as the time from the first treatment of AUTO4 to death due to any cause.\n\nPatients who had not died prior to data cut-off or database finalization were censored at the last contact date.\n\nPatients who received SCT after AUTO4 infusion were ignored in the main analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"All uncensored patients who received an infusion of AUTO4.","id":"OG000","title":"All Treated Patients Evaluable for OS"},{"description":"Patients received 25x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG001","title":"Phase I Dose Escalation - Cohort 1"},{"description":"Patients received 75x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG002","title":"Phase I Dose Escalation - Cohort 2"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG003","title":"Phase I Dose Escalation - Cohort 3"},{"description":"Patients received 450x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG004","title":"Phase I Dose Escalation - Cohort 4"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG005","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 3"},{"description":"Patients received 450x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG006","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 4"},{"description":"Patients received 900x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG007","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 5"}],"paramType":"MEDIAN","populationDescription":"Data for OS were pooled for analysis because the number of patients was \\<5 for all of the groups and the intended reverse Kaplan-Meier model cannot be built with such a small sample size","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Evaluate Overall Survival (OS) Following Treatment With AUTO4.","type":"SECONDARY","unitOfMeasure":"months"}